BG64667B1 - Дозирани форми за лечение на полова дисфункция при индивиди от женски пол - Google Patents

Дозирани форми за лечение на полова дисфункция при индивиди от женски пол Download PDF

Info

Publication number: BG64667B1
Authority: BG; Bulgaria
Prior art keywords: apomorphine; dosage form; use according; sublingual; acid addition
Prior art date: 1998-01-30

Application number

BG104715A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG104715A (bg

Inventor

Ragab El-Rashidy

Bruce Ronsen

Original Assignee

Pentech Pharmaceuticals, Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-30

Filing date

2000-08-28

Publication date

2005-11-30

2000-08-28 Application filed by Pentech Pharmaceuticals, Inc filed Critical Pentech Pharmaceuticals, Inc

2001-02-28 Publication of BG104715A publication Critical patent/BG104715A/bg

2005-11-30 Publication of BG64667B1 publication Critical patent/BG64667B1/bg

Links

201000001880 Sexual dysfunction Diseases 0.000 title claims abstract description 13
231100000872 sexual dysfunction Toxicity 0.000 title claims abstract description 13
229960004046 apomorphine Drugs 0.000 claims abstract description 76
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims abstract description 76
230000017531 blood circulation Effects 0.000 claims abstract description 33
239000002552 dosage form Substances 0.000 claims abstract description 29
230000036470 plasma concentration Effects 0.000 claims abstract description 5
230000001568 sexual effect Effects 0.000 claims description 18
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical group Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 claims description 15
229960003990 apomorphine hydrochloride Drugs 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 14
229920000858 Cyclodextrin Polymers 0.000 claims description 12
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 11
206010020565 Hyperaemia Diseases 0.000 claims description 10
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
229930195725 Mannitol Natural products 0.000 claims description 8
206010028813 Nausea Diseases 0.000 claims description 8
229960005070 ascorbic acid Drugs 0.000 claims description 8
235000010323 ascorbic acid Nutrition 0.000 claims description 8
239000011668 ascorbic acid Substances 0.000 claims description 8
230000037396 body weight Effects 0.000 claims description 8
235000010355 mannitol Nutrition 0.000 claims description 8
239000000594 mannitol Substances 0.000 claims description 8
230000008693 nausea Effects 0.000 claims description 8
239000001116 FEMA 4028 Substances 0.000 claims description 7
235000011175 beta-cyclodextrine Nutrition 0.000 claims description 7
229960004853 betadex Drugs 0.000 claims description 7
210000001259 mesencephalon Anatomy 0.000 claims description 6
102000015554 Dopamine receptor Human genes 0.000 claims description 4
108050004812 Dopamine receptor Proteins 0.000 claims description 4
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 3
-1 hydroxypropyl Chemical group 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
239000000945 filler Substances 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 18
210000005036 nerve Anatomy 0.000 abstract description 5
230000001668 ameliorated effect Effects 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 description 13
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
230000007383 nerve stimulation Effects 0.000 description 10
241000283973 Oryctolagus cuniculus Species 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
239000003826 tablet Substances 0.000 description 8
230000004064 dysfunction Effects 0.000 description 7
210000001215 vagina Anatomy 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 6
230000000982 vasogenic effect Effects 0.000 description 6
230000000638 stimulation Effects 0.000 description 5
239000006190 sub-lingual tablet Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 5
108010011485 Aspartame Proteins 0.000 description 4
238000010171 animal model Methods 0.000 description 4
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
235000010357 aspartame Nutrition 0.000 description 4
239000000605 aspartame Substances 0.000 description 4
229960003438 aspartame Drugs 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
210000003029 clitoris Anatomy 0.000 description 4
238000005461 lubrication Methods 0.000 description 4
230000002792 vascular Effects 0.000 description 4
229920003084 Avicel® PH-102 Polymers 0.000 description 3
229940098778 Dopamine receptor agonist Drugs 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
229920003102 Methocel™ E4M Polymers 0.000 description 3
239000002111 antiemetic agent Substances 0.000 description 3
230000037007 arousal Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000035487 diastolic blood pressure Effects 0.000 description 3
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 3
229960001253 domperidone Drugs 0.000 description 3
239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
230000001856 erectile effect Effects 0.000 description 3
230000000574 ganglionic effect Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000001107 psychogenic effect Effects 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229940125683 antiemetic agent Drugs 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000002895 emetic Substances 0.000 description 2
230000000004 hemodynamic effect Effects 0.000 description 2
201000001881 impotence Diseases 0.000 description 2
229960002715 nicotine Drugs 0.000 description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
230000018052 penile erection Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000036299 sexual function Effects 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 description 1
MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 description 1
YHBIGBYIUMCLJS-UHFFFAOYSA-N 5-fluoro-1,3-benzothiazol-2-amine Chemical compound FC1=CC=C2SC(N)=NC2=C1 YHBIGBYIUMCLJS-UHFFFAOYSA-N 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
AVZIYZHXZAYGJS-UHFFFAOYSA-N Difenidol hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 AVZIYZHXZAYGJS-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
229960005058 diphenidol hydrochloride Drugs 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
230000001257 erectogenic effect Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000000544 hyperemic effect Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000009245 menopause Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
BQDBKDMTIJBJLA-UHFFFAOYSA-N metopimazine Chemical compound C12=CC(S(=O)(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(C(N)=O)CC1 BQDBKDMTIJBJLA-UHFFFAOYSA-N 0.000 description 1
229960000767 metopimazine Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
RUPOLIZWSDDWNJ-UHFFFAOYSA-N oxypendyl Chemical compound C1CN(CCO)CCN1CCCN1C2=NC=CC=C2SC2=CC=CC=C21 RUPOLIZWSDDWNJ-UHFFFAOYSA-N 0.000 description 1
229950005217 oxypendyl Drugs 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
230000001734 parasympathetic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
210000002640 perineum Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000002990 phenothiazines Chemical class 0.000 description 1
OSJJYEUEJRVVOD-UHFFFAOYSA-N pipamazine Chemical compound C1CC(C(=O)N)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 OSJJYEUEJRVVOD-UHFFFAOYSA-N 0.000 description 1
229950008580 pipamazine Drugs 0.000 description 1
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
229960003111 prochlorperazine Drugs 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000000523 sample Substances 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000036332 sexual response Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940098466 sublingual tablet Drugs 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 1
229960004161 trimethobenzamide Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940072018 zofran Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Plant Substances (AREA)
Other In-Based Heterocyclic Compounds (AREA)

BG104715A 1998-01-30 2000-08-28 Дозирани форми за лечение на полова дисфункция при индивиди от женски пол BG64667B1 (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/016,252 US5945117A (en)	1998-01-30	1998-01-30	Treatment of female sexual dysfunction

Publications (2)

Publication Number	Publication Date
BG104715A BG104715A (bg)	2001-02-28
BG64667B1 true BG64667B1 (bg)	2005-11-30

Family

ID=21776169

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104715A BG64667B1 (bg)	1998-01-30	2000-08-28	Дозирани форми за лечение на полова дисфункция при индивиди от женски пол

Country Status (34)

Country	Link
US (2)	US5945117A (fr)
EP (1)	EP1056419A4 (fr)
JP (1)	JP2002501875A (fr)
KR (1)	KR20010040477A (fr)
CN (1)	CN1250221C (fr)
AR (1)	AR017976A1 (fr)
AU (1)	AU752928B2 (fr)
BG (1)	BG64667B1 (fr)
BR (1)	BR9908038A (fr)
CA (1)	CA2322289A1 (fr)
CO (1)	CO4970819A1 (fr)
CR (1)	CR5959A (fr)
DZ (1)	DZ2714A1 (fr)
GC (1)	GC0000096A (fr)
GT (1)	GT199900013A (fr)
HK (1)	HK1040901B (fr)
HN (1)	HN1999000015A (fr)
HU (1)	HUP0101268A3 (fr)
IL (2)	IL137569A0 (fr)
JO (1)	JO2085B1 (fr)
MA (1)	MA26600A1 (fr)
MX (1)	MXPA00007447A (fr)
NO (1)	NO319821B1 (fr)
NZ (1)	NZ506597A (fr)
PA (1)	PA8467801A1 (fr)
PE (1)	PE20000240A1 (fr)
PL (1)	PL194350B1 (fr)
SK (1)	SK11362000A3 (fr)
TN (1)	TNSN99008A1 (fr)
TR (1)	TR200002220T2 (fr)
TW (1)	TW550069B (fr)
UY (1)	UY25374A1 (fr)
WO (1)	WO1999038467A1 (fr)
ZA (1)	ZA99686B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020165122A1 (en) *	1994-04-22	2002-11-07	Heaton Jeremy P. W.	Method and compositions for the treatment or amelioration of female sexual dysfunction
US6395744B1 (en) *	1994-04-22	2002-05-28	Queen's University At Kingston	Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) *	1996-02-02	2005-03-24	Nitromed, Inc.	Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en)	1997-10-31	2002-10-29	Nitromed, Inc.	Methods for treating female sexual dysfunctions
US5945117A (en) *	1998-01-30	1999-08-31	Pentech Pharmaceuticals, Inc.	Treatment of female sexual dysfunction
AU2003204720B2 (en) *	1998-05-29	2006-06-29	Tap Pharmaceutical Products Inc.	Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
WO1999066909A2 (fr) *	1998-06-22	1999-12-29	Univ Kingston	Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme
US20050245494A1 (en) *	1999-07-01	2005-11-03	40 J's Llc	Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20050070499A1 (en) *	1999-11-08	2005-03-31	Pfizer Inc.	Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) *	2000-03-20	2001-10-16	Abbott Lab	Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
CN1471395A (zh)	2000-04-07	2004-01-28	��ҽҩƷ��޹�˾	阿扑吗啡衍生物及其使用方法
DE60131644T2 (de)	2000-05-09	2008-10-30	Nitromed, Inc., Lexington	Infrarotthermographie und behandlung von sexuellen dysfunktionen
EP1328281B1 (fr) *	2000-06-27	2007-08-15	Qualilife Pharmaceuticals Inc.	Compositions et procedes pour le traitement de l'excitation sexuelle chez la femme
US7223406B2 (en) *	2000-07-21	2007-05-29	The Regents Of The University Of California	Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1365794A2 (fr)	2000-07-21	2003-12-03	Lue, Tom	Methodes et compositions destinees a prevenir et traiter la dyserection chez l'homme et les troubles de l'excitation sexuelle chez la femme
US20020065286A1 (en) *	2000-08-21	2002-05-30	Davies Michael John	Treatment of wounds
WO2002039879A2 (fr)	2000-11-15	2002-05-23	Tap Pharmaceutical Products, Inc.	Traitement d'un dysfonctionnement sexuel entraine par une medication antidepressive par apomorphine
BR0110450A (pt) *	2000-11-22	2005-02-09	Abbott Lab	Uso de agonistas receptores d4 de dopamina seletivo para tratamento de disfunção sexual
WO2002062315A1 (fr) *	2001-02-08	2002-08-15	Pharmacia Corporation	Medicament a action rapide pour le traitement de dysfonctionnements sexuels
EP1496915A1 (fr) *	2002-03-19	2005-01-19	Brain 'N' Beyond Biotech	Derives de glycoside et de glycoside orthoester d'apomorphine, d'analogues et utilisations correspondantes
US20030219696A1 (en) *	2002-05-23	2003-11-27	Moreland Gerald W.	Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en)	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
GB0221711D0 (en) *	2002-09-19	2002-10-30	Ardana Bioscience Ltd	Methods
US20040138291A1 (en) *	2002-10-10	2004-07-15	Adams Michael A.	Treatment of sexual dysfunction
CA2451267A1 (fr) *	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Utilisations pharmaceutiques de ligands alpha2delta
US20040204439A1 (en) *	2003-04-14	2004-10-14	Staniforth John Nicholas	Composition, device, and method for treating sexual dysfunction via inhalation
WO2004089374A1 (fr) *	2003-04-14	2004-10-21	Vectura Ltd	Compositions pharmaceutiques comprenant de l'apomorphine pour l'inhalation pulmonaire
US7276246B2 (en) *	2003-05-09	2007-10-02	Cephalon, Inc.	Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en)	2003-05-09	2007-12-11	Cephalon, Inc.	Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) *	2003-06-17	2003-07-23	Pfizer Ltd	Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) *	2003-08-08	2005-03-10	Pfizer Inc	Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) *	2003-08-20	2005-03-24	Lts Lohmann Therapie-Systeme Ag	Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) *	2003-09-22	2007-11-06	Pfizer Inc.	Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) *	2004-04-30	2004-06-09	Pfizer Ltd	Novel compounds
AP2006003771A0 (en) *	2004-04-30	2006-10-31	Warner Lambert Co	Substituted morpholine compounds for the treatmentof central nervous system disorders
JP2008533193A (ja) *	2005-03-21	2008-08-21	ファイザー・リミテッド	オキシトシン拮抗薬としての置換トリアゾール誘導体
ES2313626T3 (es) *	2005-03-21	2009-03-01	Pfizer Limited	Derivados de triazol sustituidos como antagonistas de oxitocina.
WO2006105615A1 (fr) *	2005-04-08	2006-10-12	Ozpharma Pty Ltd	Procede d’administration orale
WO2007017752A1 (fr) *	2005-08-10	2007-02-15	Pfizer Limited	Derives de triazole substitues en tant qu'antagonistes d'oxytocine
US8349850B2 (en) *	2006-03-28	2013-01-08	Atir Holding S.A.	Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US7800094B2 (en) *	2007-06-11	2010-09-21	Macronix International Co., Ltd.	Resistance memory with tungsten compound and manufacturing
CA2765291C (fr) *	2009-06-12	2016-03-08	Adagio Pharmaceuticals Ltd.	Apomorphine sublinguale
WO2011130608A1 (fr) *	2010-04-15	2011-10-20	Life Science Enhancement Corporation	Procédés et compositions pour stimuler l'excitation sexuelle chez la femme et traiter un trouble sexuel chez la femme
KR101890317B1 (ko) *	2010-12-16	2018-08-22	선오비온 파마슈티컬스 인코포레이티드	설하 필름
US9353067B2 (en)	2011-04-10	2016-05-31	Atir Holding S.A.	Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (fr)	2011-07-11	2013-01-16	Britannia Pharmaceuticals Limited	Nouvelle composition thérapeutique contenant de l'apomorphine en tant que principe actif
EP3285771B1 (fr)	2015-04-21	2025-02-12	Sunovion Pharmaceuticals Inc.	Méthodes de traitement de la maladie de parkinson par l'administration d'apomorphine à une muqueuse orale

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4521421A (en) *	1983-09-26	1985-06-04	Eli Lilly And Company	Treatment of sexual dysfunction
WO1993023035A2 (fr) *	1992-05-18	1993-11-25	Smithkline Beecham Plc	Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson
US5565466A (en) *	1993-08-13	1996-10-15	Zonagen, Inc.	Methods for modulating the human sexual response
PT758895E (pt) *	1994-04-22	2000-05-31	Univ Kingston	Formas de dosagem sublingual contendo apomorfina para uso no tratamento da disfuncao erectil
US5562917A (en) *	1994-12-23	1996-10-08	Pentech Pharmaceuticals, Inc.	Transdermal administration of apomorphine
US5624677A (en) *	1995-06-13	1997-04-29	Pentech Pharmaceuticals, Inc.	Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) *	1998-01-30	1999-08-31	Pentech Pharmaceuticals, Inc.	Treatment of female sexual dysfunction

1998
- 1998-01-30 US US09/016,252 patent/US5945117A/en not_active Expired - Fee Related
1999
- 1999-01-21 TN TNTNSN99008A patent/TNSN99008A1/fr unknown
- 1999-01-28 EP EP99905497A patent/EP1056419A4/fr not_active Withdrawn
- 1999-01-28 IL IL13756999A patent/IL137569A0/xx active IP Right Grant
- 1999-01-28 WO PCT/US1999/001776 patent/WO1999038467A1/fr not_active Ceased
- 1999-01-28 CR CR5959A patent/CR5959A/es not_active Application Discontinuation
- 1999-01-28 MX MXPA00007447A patent/MXPA00007447A/es not_active IP Right Cessation
- 1999-01-28 SK SK1136-2000A patent/SK11362000A3/sk unknown
- 1999-01-28 JO JO19992085A patent/JO2085B1/en active
- 1999-01-28 CA CA002322289A patent/CA2322289A1/fr not_active Abandoned
- 1999-01-28 TR TR2000/02220T patent/TR200002220T2/xx unknown
- 1999-01-28 HK HK02101988.0A patent/HK1040901B/zh not_active IP Right Cessation
- 1999-01-28 AU AU25644/99A patent/AU752928B2/en not_active Ceased
- 1999-01-28 HU HU0101268A patent/HUP0101268A3/hu unknown
- 1999-01-28 CN CNB998044423A patent/CN1250221C/zh not_active Expired - Fee Related
- 1999-01-28 KR KR1020007008333A patent/KR20010040477A/ko not_active Ceased
- 1999-01-28 ZA ZA9900686A patent/ZA99686B/xx unknown
- 1999-01-28 JP JP2000529203A patent/JP2002501875A/ja not_active Withdrawn
- 1999-01-28 BR BR9908038-9A patent/BR9908038A/pt not_active Application Discontinuation
- 1999-01-28 NZ NZ506597A patent/NZ506597A/en unknown
- 1999-01-28 HN HN1999000015A patent/HN1999000015A/es unknown
- 1999-01-28 PL PL99342062A patent/PL194350B1/pl unknown
- 1999-01-29 AR ARP990100389A patent/AR017976A1/es not_active Application Discontinuation
- 1999-01-29 CO CO99005067A patent/CO4970819A1/es unknown
- 1999-01-29 UY UY25374A patent/UY25374A1/es not_active Application Discontinuation
- 1999-01-29 PA PA19998467801A patent/PA8467801A1/es unknown
- 1999-01-29 MA MA25442A patent/MA26600A1/fr unknown
- 1999-01-29 PE PE1999000067A patent/PE20000240A1/es not_active Application Discontinuation
- 1999-01-29 TW TW088101384A patent/TW550069B/zh not_active IP Right Cessation
- 1999-01-30 DZ DZ990015A patent/DZ2714A1/fr active
- 1999-01-31 GC GCP199973 patent/GC0000096A/xx active
- 1999-07-02 US US09/345,009 patent/US6193992B1/en not_active Expired - Fee Related
2000
- 2000-07-27 NO NO20003845A patent/NO319821B1/no unknown
- 2000-07-27 IL IL137569A patent/IL137569A/en unknown
- 2000-08-28 BG BG104715A patent/BG64667B1/bg unknown
2001
- 2001-07-20 GT GT199900013A patent/GT199900013A/es unknown

Also Published As

Publication number	Publication date
GC0000096A (en)	2005-06-29
NZ506597A (en)	2003-07-25
EP1056419A4 (fr)	2007-05-02
JO2085B1 (en)	2000-05-21
SK11362000A3 (sk)	2001-02-12
TR200002220T2 (tr)	2000-12-21
AR017976A1 (es)	2001-10-24
HUP0101268A2 (hu)	2001-09-28
CO4970819A1 (es)	2000-11-07
CN1250221C (zh)	2006-04-12
KR20010040477A (ko)	2001-05-15
GT199900013A (es)	2001-07-20
AU752928B2 (en)	2002-10-03
JP2002501875A (ja)	2002-01-22
CR5959A (es)	1999-07-28
TW550069B (en)	2003-09-01
UY25374A1 (es)	1999-09-27
TNSN99008A1 (fr)	2005-11-10
BG104715A (bg)	2001-02-28
IL137569A (en)	2006-08-01
US6193992B1 (en)	2001-02-27
ZA99686B (en)	1999-07-28
HK1040901A1 (en)	2002-06-28
EP1056419A1 (fr)	2000-12-06
PA8467801A1 (es)	2000-09-29
HK1040901B (zh)	2006-11-24
PL342062A1 (en)	2001-05-21
NO20003845L (no)	2000-09-28
HN1999000015A (es)	1999-08-23
WO1999038467A1 (fr)	1999-08-05
CN1313742A (zh)	2001-09-19
NO20003845D0 (no)	2000-07-27
PE20000240A1 (es)	2000-03-31
BR9908038A (pt)	2002-01-02
IL137569A0 (en)	2001-07-24
US5945117A (en)	1999-08-31
PL194350B1 (pl)	2007-05-31
AU2564499A (en)	1999-08-16
HUP0101268A3 (en)	2002-12-28
NO319821B1 (no)	2005-09-19
MA26600A1 (fr)	2004-12-20
DZ2714A1 (fr)	2003-09-01
MXPA00007447A (es)	2006-01-25
CA2322289A1 (fr)	1999-08-05

Publication	Publication Date	Title
US5945117A (en)	1999-08-31	Treatment of female sexual dysfunction
EP0758895B1 (fr)	2000-01-26	Formes galeniques sublinguales contenant de l'apomorphine pour l'utilisation dans le traitement du dysfonctionnement erectile
ES2244418T3 (es)	2005-12-16	Composiciones de apomorfina y sidenalfilo y utilizacion de los mismos para el tratamiento de la disfuncion erectil.
US6121276A (en)	2000-09-19	Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US6566368B2 (en)	2003-05-20	Apomorphine-containing dosage form for ameliorating male erectile dysfunction
CZ20002755A3 (cs)	2000-12-13	Způsob zlepšení ženské sexuální dysfunkce
HK1014239B (en)	2001-02-09	Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction
HK1025742B (en)	2006-10-13	Sublingual composition containing apomorphine for diagnosing functional impotence